Targeted fibrosis screening flags fewer without missing disease

Researchers have developed a targeted fibrosis screening strategy that reduces the number of adults flagged for testing, doubling case detection while maintaining low risk for future liver disease in those not eligible for screening.
Current guidelines from AGA, American Association for the Study of Liver Diseases and European Association for the Study of the Liver identified 60% to 76% of the U.S. population as eligible for fibrosis screening.
“The major issue with current recommendations is that they are overly broad,” lead study author Laurens A. van Kleef, MD, PhD, a postdoctoral researcher





